Jonghoon Lim, CEO of Hanmi Fine Chemical and the second son of the late Sung-ki Lim, former chairman of Hanmi Group, has sold his shares in Hanmi Science, the group's holding company.


According to the Financial Supervisory Service's electronic disclosure system on July 2, CEO Lim signed an off-market sale agreement to dispose of 1,709,788 common shares (2.50%) of Hanmi Science to the Now IB No. 22 Fund. The sale price was set at 48,000 won per share, with the total transaction amounting to 82,069,820,000 won. The deal is scheduled to close on August 5, 2026.

Jonghoon Lim, CEO of Hanmi Fine Chemical. Photo by Younghan Heo

Jonghoon Lim, CEO of Hanmi Fine Chemical. Photo by Younghan Heo

View original image

As a result of this sale, CEO Lim's stake will decrease from 5.09% (3,483,808 shares) to 2.59% (1,774,020 shares). While the disclosed purpose of the transaction was to secure cash liquidity through the sale of shares, the deal is expected to have a significant impact on the balance of power in the group's management structure. Previously, Dongguk Shin, chairman of Hanyang Precision, had reportedly attempted to acquire CEO Lim's stake by raising approximately 300 billion won, but CEO Lim declined the offer. Unlike his older brother Jongyoon Lim, chairman of Coree Group, who sold his shares to Chairman Shin's side, CEO Lim sold his stake to investors considered allied with Chairman Song's mother-daughter faction.


CEO Lim stated, "This was a carefully considered decision made to sincerely carry on my father's management philosophy. I hope this will eliminate unnecessary controversy and foster an environment that enables us to accelerate our business. Together with my mother and sister, I will do everything I can to help realize my father's vision of building a strong pharmaceutical nation and to contribute to the company's growth," expressing his commitment to stabilizing the group's governance.



Currently, Chairman Shin and the mother-daughter faction are embroiled in ongoing legal disputes over a four-party shareholder agreement. Chairman Shin holds a total 29.83% stake in Hanmi Science, combining his personal stake of 22.88% with Hanyang Precision's 6.95%. Industry observers expect that, as a result of this transaction, the mother-daughter faction—now controlling about 40% of friendly shares, including those held by La Defense Partners—will have considerable influence over the future management structure of Hanmi Group.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing